FTLF Fitlife Brands (FTLF) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001374328
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
23
13F, latest reported quarter
What the filings say about FTLF
Insiders, 180 days
+$10.2K net bought
1 buyer
Fitlife Brands insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, FITLIFE BRANDS, INC. insiders bought a net $10.2K of stock across 16 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,000 shares held after it.
- No other insider bought within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pappas Shannon K. bought about $10.2K of FTLF on Aug 19, 2026; 23 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 14, 2025.
- +8.0% median (+8.0% mean) 90-day return after 2 previous buys.
- The trade is 34.1% of the 8,800 shares held after it.
- 1 other insider bought within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lingenbrink Matthew bought about $29.3K of FTLF on Apr 10, 2026; 1 other insider bought within 30 days and 23 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.9% of the 158,000 shares held after it.
- 1 other insider bought within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dawson Grant Robert bought about $29.9K of FTLF on Apr 10, 2026; 1 other insider bought within 30 days and 23 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 15, 2025.
- -1.9% median (-8.1% mean) 90-day return after 3 previous buys.
- The trade is 27.7% of the 593 shares held after it.
- No other insider bought within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Yakatan Seth bought about $2.5K of FTLF on Jan 15, 2026; 23 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 15, 2025.
- -0.5% median (-0.5% mean) 90-day return after 2 previous buys.
- The trade is 32.4% of the 429 shares held after it.
- No other insider bought within 30 days.
- 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Yakatan Seth bought about $2.5K of FTLF on Dec 15, 2025; 23 funds added in the latest 13F quarter.16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$10.2K over 180 days
+$10.2K over 90 days
more than 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
23 funds bought in last quarter
below 66% of Pharma & Biotech
Revenue
-75.3% year over year
below 86% of Pharma & Biotech
Margin
12.7% net margin
more than 83% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.5% of the float short (float per yahoo 2026-10-26) · 6.7 days to cover · settled 2026-09-30
below 77% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch FTLF
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-56.5%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns FTLF: institutional holders (13F)
13F holdings, latest reported quarter
154,255 sh
$1.7M
145,000 sh
$1.6M
49,045 sh
$540.3K
46,637 sh
$513.5K
35,275 sh
$388.4K
Congress trades in FTLF
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
FTLF planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
FTLF mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Applied Finance IVS US SMID ETF
$3.3K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$143.5K position · as of 2026-06-30
0.0%
Invesco Russell 2000 Dynamic Multifactor ETF
$13.0K position · as of 2026-05-31
0.0%
1290 VT Micro Cap Portfolio
$10.1K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$38.4K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$16.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$598.8K
$598.8K
$332.4K
+104%
n/a
2024
$578.0K
$634.6K
$299.8K
+104%
n/a
2023
$532.0K
$637.1K
$282.7K
+19%
n/a
2022
$475.5K
$411.0K
$241.5K
+0%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $10.2K bought by insiders over 180 days, 23 funds added last quarter. Each figure is a federal filing, dated the day it went public.
FTLF financials
Revenue growth
-75.3%
XBRL, annual
Net margin
12.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$101.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM FTLF
| FY Dec 2025 | $81.5M |
| FY Dec 2024 | $64.5M |
| FY Dec 2023 | $52.7M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $26.5M |
| Mar 2026 | $25.3M |
| Dec 2025 | $25.9M |
| Sep 2025 | $23.5M |
| Jun 2025 | $16.1M |
| Mar 2025 | $15.9M |
| Dec 2024 | $15.0M |
| Sep 2024 | $16.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+6.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM FTLF
| FY Dec 2025 | +7.8% |
| FY Dec 2024 | +13.9% |
| FY Dec 2023 | +10.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +7.3% |
| Mar 2026 | +6.8% |
| Dec 2025 | +6.3% |
| Sep 2025 | +3.9% |
| Jun 2025 | +10.8% |
| Mar 2025 | +12.7% |
| Dec 2024 | +13.8% |
| Sep 2024 | +13.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$10.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM FTLF
| FY Dec 2025 | $7.4M |
| FY Dec 2024 | $9.6M |
| FY Dec 2023 | $4.1M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $3.6M |
| Mar 2026 | $2.5M |
| Dec 2025 | $239.0K |
| Sep 2025 | $3.7M |
| Jun 2025 | $1.2M |
| Mar 2025 | $2.3M |
| Dec 2024 | $957.0K |
| Sep 2024 | $2.0M |
At each fiscal year end
Single quarter
Debt to equity
0.98x
long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end); equity 2026-06-30
Debt to equity FTLF
| FY Dec 2025 | 1.06x |
| FY Dec 2024 | 0.36x |
| FY Dec 2023 | 0.67x |
| FY Dec 2022 | 0.00x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.98x |
| Mar 2026 | 1.02x |
| Dec 2025 | 1.06x |
| Sep 2025 | 1.11x |
| Jun 2025 | 0.26x |
| Mar 2025 | 0.31x |
| Dec 2024 | 0.36x |
| Sep 2024 | 0.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.22x
TTM operating cash flow over long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end)
Cash flow to debt FTLF
| FY Dec 2025 | 0.16x |
| FY Dec 2024 | 0.74x |
| FY Dec 2023 | 0.23x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.22x |
| Mar 2026 | 0.16x |
| Dec 2025 | 0.16x |
| Sep 2025 | 0.18x |
| Jun 2025 | 0.60x |
| Mar 2025 | 0.58x |
| Dec 2024 | 0.74x |
| Sep 2024 | 0.83x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+14.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity FTLF
| FY Dec 2025 | +15.9% |
| FY Dec 2024 | +28.4% |
| FY Dec 2023 | +21.9% |
| FY Dec 2022 | +22.9% |
| FY Dec 2021 | +37.0% |
| Jun 2026 | +14.1% |
| Mar 2026 | +14.3% |
| Dec 2025 | +15.9% |
| Sep 2025 | +17.8% |
| Jun 2025 | +21.9% |
| Mar 2025 | +25.9% |
| Dec 2024 | +28.4% |
| Sep 2024 | +28.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets FTLF
| FY Dec 2025 | +7.7% |
| FY Dec 2024 | +15.8% |
| FY Dec 2023 | +13.1% |
| FY Dec 2022 | +18.8% |
| FY Dec 2021 | +28.4% |
| Jun 2026 | +7.5% |
| Mar 2026 | +7.2% |
| Dec 2025 | +7.7% |
| Sep 2025 | +8.0% |
| Jun 2025 | +13.3% |
| Mar 2025 | +15.0% |
| Dec 2024 | +15.8% |
| Sep 2024 | +16.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+3.3%
operating income after a 27.5% effective tax rate, over long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital FTLF
| FY Dec 2025 | +2.7% |
| FY Dec 2024 | +25.3% |
| FY Dec 2023 | +15.5% |
| FY Dec 2022 | +30.9% |
| FY Dec 2021 | +54.1% |
| Jun 2026 | +3.3% |
| Mar 2026 | +2.7% |
| Dec 2025 | +2.7% |
| Sep 2025 | +9.6% |
| Jun 2025 | +20.6% |
| Mar 2025 | +23.7% |
| Dec 2024 | +25.3% |
| Sep 2024 | +25.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed FTLF
| FY Dec 2025 | +4.5% |
| FY Dec 2024 | +28.4% |
| FY Dec 2023 | +22.7% |
| FY Dec 2022 | +29.3% |
| FY Dec 2021 | +41.6% |
| Jun 2026 | +5.9% |
| Mar 2026 | +4.6% |
| Dec 2025 | +4.5% |
| Sep 2025 | +17.3% |
| Jun 2025 | +24.3% |
| Mar 2025 | +27.4% |
| Dec 2024 | +28.4% |
| Sep 2024 | +29.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
43.79x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing FTLF
| FY Dec 2025 | 81.35x |
| FY Dec 2024 | 18.11x |
| FY Dec 2023 | 17.69x |
| FY Dec 2022 | 8.96x |
| FY Dec 2021 | 7.08x |
| Jun 2026 | 57.95x |
| Mar 2026 | 83.53x |
| Dec 2025 | 81.35x |
| Sep 2025 | 29.25x |
| Jun 2025 | 16.28x |
| Mar 2025 | 13.60x |
| Dec 2024 | 18.11x |
| Sep 2024 | 36.38x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$116.2M
market value at close 2026-10-26 on 2026-08-12 shares, plus long-term 2025-09-30 (9 months older than the period end) plus current 2025-09-30 (9 months older than the period end), minus cash 2021-06-30
Enterprise value FTLF
| FY Dec 2025 | $190.8M |
| FY Dec 2024 | $79.6M |
| FY Dec 2023 | $53.4M |
| FY Dec 2022 | $27.8M |
| FY Dec 2021 | $580.5K |
| Jun 2026 | $141.4M |
| Mar 2026 | $171.4M |
| Dec 2025 | $190.8M |
| Sep 2025 | $224.8M |
| Jun 2025 | $124.7M |
| Mar 2025 | $115.1M |
| Dec 2024 | $79.6M |
| Sep 2024 | $79.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+12.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield FTLF
| FY Dec 2025 | +4.8% |
| FY Dec 2024 | +12.8% |
| FY Dec 2023 | +9.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +9.7% |
| Mar 2026 | +5.7% |
| Dec 2025 | +4.8% |
| Sep 2025 | +4.3% |
| Jun 2025 | +5.3% |
| Mar 2025 | +6.2% |
| Dec 2024 | +12.8% |
| Sep 2024 | +13.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -76%, PEG needs growth
PEG, trailing FTLF
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.27x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 0.57x |
| Jun 2025 | 0.46x |
| Mar 2025 | 0.58x |
| Dec 2024 | 0.27x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $81.5M | $64.5M | $52.7M | $28.8M |
| Gross profit | $6.9M | $28.1M | $21.4M | $12.0M |
| Operating income | $3.0M | $13.1M | $7.5M | $5.7M |
| Net income | $6.3M | $9.0M | $5.3M | $4.4M |
| EPS (diluted) | 0.20 | 0.91 | 0.54 | 0.89 |
| Operating cash flow | $7.4M | $9.6M | $4.2M | $4.1M |
| Long-term debt | n/a | $8.6M | $15.5M | $0 |
| Buybacks | n/a | n/a | $0 | $779.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
FTLF Stock Sonar score 6/7 axes
Find similar shapesCompareFTLF ranks highest on risk and compliance (82nd percentile) and profitability (69th), and lowest on growth (14th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
FTLF filings, in plain words
Are Fitlife Brands insiders buying or selling FTLF?
In the 180 days to 2026-10-28, Fitlife Brands insiders were net buyers, a net $10.2K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Fitlife Brands insiders were net buyers of FTLF, a net $10.2K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
